Additionally, PDLIM2 degrades STAT3 and the intranuclear transcription factor RelA (p65) through the ubiquitination-proteasome pathway, which exerts a cancer-inhibiting effect and thus inhibits the pathological process of lung cancer (Tanaka et al., 2007). Here, PDLIM2 is linked to lung carcinoma.